Coherus Oncology, Inc. - CHRS
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Timothy G. Youngquist 2020 Irrevocable Trust | 8.3% | 12,750,800 | View |
| May 11, 2026 | SCHEDULE 13G/A | Timothy G. Youngquist 2020 Irrevocable Trust | — | — | View |
| Apr 29, 2026 | SCHEDULE 13G/A | Thomas A. Satterfield, Jr. | 4.6% | 6,930,000 | View |
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 05, 2026 | SCHEDULE 13G | Timothy G. Youngquist 2020 Irrevocable Trust | 6.5% | 7,850,800 | View |
| Jan 30, 2026 | SCHEDULE 13G/A | The Vanguard Group | 8.29% | 10,028,893 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.